Form D — Dualitas Therapeutics, Inc.
0001231919-25-000517 · filed Nov 18, 2025
Offering
- Industry
- Biotechnology
- Exemptions
- 06b
- Total offering
- $66,599,990
- Total sold
- $32,599,997
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Dualitas Therapeutics, Inc.
- CIK
- 2091994
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- 2023
- Address
- 681 GATEWAY BOULEVARD, SUITE 411
SOUTH SAN FRANCISCO, CA 94080 - Phone
- (917) 640-1086
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Richard Murray · Executive OfficerSouth San Francisco, CA Find on LinkedIn ↗
-
Forbes Huang · Executive OfficerSouth San Francisco, CA Find on LinkedIn ↗
-
Nikola Trbovic · DirectorSouth San Francisco, CA Find on LinkedIn ↗
-
Neil Weir · DirectorSouth San Francisco, CA Find on LinkedIn ↗
-
Alicia Levey · DirectorSouth San Francisco, CA Find on LinkedIn ↗
-
Thomas Hudson · DirectorSouth San Francisco, CA Find on LinkedIn ↗
-
Mark McDade · DirectorSouth San Francisco, CA Find on LinkedIn ↗
-
Greg Lazar · Executive OfficerSouth San Francisco, CA Find on LinkedIn ↗
-
Michael Ross · DirectorSouth San Francisco, CA Find on LinkedIn ↗
View the original filing on SEC EDGAR ↗